The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

The Global Biosimilars Market size is projected to be valued at USD 27.20 billion in 2023 and reach USD 76.20 billion by 2030, growing at a CAGR of 15.9% according to a new report by The Research ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Total aggregate value of the drugs generating the highest sales in 2024 rose 6.5% vs. 2023, and jumped 53% over five years.